Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of RAY1225 in Healthy and Obese Participants
NCT05835752Phase 1Completed
- Sponsor
- Raynovent Biotech
- Start
- May 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RAY1225 in obesity, sponsored by Raynovent Biotech. Primary endpoint: Number and severity of participants with Treatment Emergent Adverse Events and Serious Adverse Events at Day 29. Started May 2023; status: completed.
02
Drugs
RAY1225
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05835752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05835752.